Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Allen B. King"'
Autor:
Kitty Poon, Allen B King
Publikováno v:
Drug, Healthcare and Patient Safety, Vol 2010, Iss default, Pp 213-223 (2010)
Kitty Poon, Allen B KingDiabetes Care Center, Salinas, CA, USAAbstract: Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase
Externí odkaz:
https://doaj.org/article/3dc490031fa848c1a61caed1d91af076
Autor:
Allen B. King
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 23(3)
Autor:
Allen B. King
Publikováno v:
Endocrine Practice. 27:642
Autor:
Allen B. King
Publikováno v:
Diabetes. 68
The current dosing guidelines suggesting TBD is ~ 50% of TDD and TBD = 0.5 U/kg (in T2DM) were based on uncontrolled studies. We have previously published separate controlled studies in pump-treated type 1 (n=39) and type 2 (n=30), multiple daily dos
Autor:
Jillaine Socha, Allen B. King
Publikováno v:
Diabetes. 68
The accepted bolus dosing factor estimation formulas are CIR = 450/TDD and CF = 1700/TDD. These formulas were not based on controlled studies. We have combined two of our previously published well-controlled studies to reevaluate these relationships.
Autor:
Allen B. King
Publikováno v:
Diabetes. 68
Basal insulin is titrated upward whenever the average of several days’ FG exceeds a goal. It is assumed that averaging better reflects the ‘true’ FG (Central Limit Theorem) but this is true only if they are normatively distributed. There are a
Autor:
Daniel Einhorn, Allen B. King, Yehuda Handelsman, Lars Endahl, Henriette Mersebach, Bruce W. Bode
Publikováno v:
Endocrine Practice. 21:917-926
Meta-analysis to compare hypoglycemia rates of basal insulin degludec (IDeg) with insulin glargine (IGlar) in patients with diabetes achieving good glycemic control (hemoglobin A1c [HbA1c]7% at end of trial).In a preplanned meta-analysis, patient dat
Autor:
Allen B. King
Publikováno v:
Journal of Diabetes Science and Technology. 9:1342-1345
Because of its ease and simplicity of its measurement, the morning fasting plasma glucose (FPG), has been as used a surrogate marker for the entire basal day when titrating once-nightly basal insulin. Common in obese insulin-treated patients with typ